Business Context and Reporting Period
This Form 8-K Current Report was filed by Rockwell Medical, Inc. (Nasdaq: RMTI) on December 12, 2024, covering events occurring on December 10, 2024. The filing addresses Item 5.02 regarding the appointment of certain officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
Material Changes
On December 10, 2024, Jesse Neri was appointed as Senior Vice President and Chief Financial Officer, effective immediately. Mr. Neri also assumes the role of Principal Financial Officer. He previously served as the Company's Senior Vice President, Finance since October 2023 and Principal Accounting Officer since January 2024.
Management Commentary, Risks, and Unusual Items
The filing details the terms of Mr. Neri's employment agreement dated October 16, 2023:
- Compensation: Annualized base salary of $300,000 (subject to adjustment) and a target performance bonus of 45% of base salary.
- Equity: An initial grant of time-based options to purchase 75,000 shares of common stock, vesting in equal installments over four years starting October 16, 2023. These options were issued outside the stockholder-approved 2018 Long-Term Incentive Plan per Nasdaq Listing Rule 5635(c)(4).
- Termination Provisions:
- Death/Disability: Full acceleration of time-based equity awards.
- Without Cause/Good Reason: One year of base salary paid in installments, COBRA reimbursement for up to one year, and continued vesting of time-based awards for one year.
- Change of Control: Severance equal to 1.5 times base salary plus 100% of the target bonus, COBRA reimbursement, and full acceleration of time-based equity awards.
Investor Verification Checklist
- Verify the impact of the 75,000 share option grant on existing dilution metrics.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Disability."
- Confirm the status of the Company's stockholder-approved 2018 Long-Term Incentive Plan regarding future grants.
- Assess the potential cash outflow implications of the severance provisions in the event of a Change of Control.